PATH | VRL
Menu

Meningococcal Serogroup W135 in the African Meningitis Belt: Epidemiology, Immunity, and Vaccines

This article, published in Expert Review of Vaccines, summarizes the existing data on Neisseria meningitidis W135 epidemiology, immunology, and vaccines as they relate to meningitis in sub-Saharan Africa. Public health approaches to meningitis epidemics have assumed that serogroup A causes the most disease in the meningitis belt; however, during 2001 and 2002, the first large-scale epidemics of serogroup W135 were reported from Burkina Faso. This has led to new issues related to public health approaches to combating meningitis outbreaks, including the need for improved laboratory diagnostics for identifying serogroups during epidemics, an affordable supply of serogroup W135-containing polysaccharide vaccine for epidemic control, and re-evaluating the long-term strategy of developing a monovalent A conjugate vaccine for the region. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)

Author: Mueller JE, Borrow R, Gessner BD

Published: 2006

» Visit web page (English)

(Located at www.ncbi.nlm.nih.gov)

Citation: Mueller JE, Borrow R, Gessner BD. Meningococcal Serogroup W135 in the African Meningitis Belt: Epidemiology, Immunity, and Vaccines. Expert Review of Vaccines. 2006;5(3):319-336.

Resource types: Peer-reviewed journal

Diseases/vaccines: Meningococcus

Topics: Disease burden and surveillance, Disease/vaccine specific information

Regions: Africa